The Association between Intranasal Esketamine and Treatment-emergent Insomnia in the Treatment of Treatment-resistant Major Depression: A Meta-analysis.
Clinical Psychopharmacology and Neuroscience August 31, 2025 Cagdas Türkmen, Rutger Boesjes, Anne-Fleur Zandbergen et al.
Intranasal (IN) esketamine represents a novel add-on treatment for treatment-resistant depression (TRD) with reported favourable effects on insomnia. IN esketamine treatment might similarly reduce the incidence of insomnia as an adverse event (AE). The present meta-analysis therefore investigated whether IN esketamine relative to placebo is associated with a lower incidence of insomnia as an AE...
DOI: 10.9758/cpn.25.1271 (opens in new tab)
Full text (opens in new tab)
Adverse drug event
Depressive disorder, major
Esketamine: esketamine
New treatment
+6